CCCarol Conrad

Carol Conrad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carol Conrad has a total of 296 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The US national registry for childhood interstitial and diffuse lung disease: Report of study design and initial enrollment cohort

    by Rebekah J. Nevel, Gail H. Deutsch, Daniel Craven, Robin Deterding, Martha P. Fishman, Jennifer A. Wambach, Alicia Casey, Katie Krone, Deborah R. Liptzin, Michael G. O'COnnor, et al.

    Introduction: Childhood interstitial and diffuse lung disease (chILD) encompasses a broad spectrum of rare disorders. The Children's Interstitial and Diffuse Lung Disease Research Network (chILDRN) established a prospective registry to advance knowledge regarding etiology, phenotype, natural history, and management of these disorders.Methods: This longitudinal, observational, multicenter registry utilizes single‐IRB reliance agreements, with participation from 25 chILDRN centers across the U.S. Clinical data are collected and managed using the Research Electronic Data Capture (REDCap) electronic data platform.Results: We report the study design and selected elements of the initial Registry enrollment cohort, which includes 683 subjects with a broad range of chILD diagnoses. The most common diagnosis reported was neuroendocrine cell hyperplasia of infancy, with 155 (23%) subjects. Components of underlying disease biology were identified by enrolling sites, with cohorts of interstitial fibrosis, immune dysregulation, and airway disease being most commonly reported. Prominent morbidities affecting enrolled children included home supplemental oxygen use (63%) and failure to thrive (46%).Conclusion: This Registry is the largest longitudinal chILD cohort in the United States to date, providing a powerful framework for collaborating centers committed to improving the understanding and treatment of these rare disorders.


  • Open Access

    The U.S. National Registry for Childhood Interstitial and Diffuse Lung Disease: Report of Study Design and Initial Enrollment Cohort

    by Rebekah Nevel, Gail Deutsch, Daniel Craven, Robin Deterding, Martha Fishman, Jennifer Wambach (Guest Editor), Alicia Casey, Katie Krone, Deborah R. Liptzin, Michael O'Connor, et al.

    Childhood interstitial and diffuse lung disease (chILD) encompasses a broad spectrum of rare disorders. The Children’s Interstitial and Diffuse Lung Disease Research Network (chILDRN) established a prospective registry to advance knowledge regarding etiology, phenotype, natural history, and management of these disorders. This longitudinal, observational, multicenter registry utilizes single-IRB reliance agreements, with participation from 25 chILDRN centers across the U.S. Clinical data are collected and managed using the Research Electronic Data Capture (REDCap) electronic data platform. We report the study design and some elements of the initial Registry enrollment cohort, which includes 683 subjects with a broad range of chILD diagnoses. The most common diagnosis reported was neuroendocrine cell hyperplasia of infancy (NEHI), with 155 (23%) subjects. Components of underlying disease biology were identified by enrolling sites, with cohorts of interstitial fibrosis, immune dysregulation, and airway disease being most commonly reported. Prominent morbidities affecting enrolled children included home supplemental oxygen use (63%) and failure to thrive (46%). This Registry is the largest longitudinal chILD cohort in the U.S. to date, providing a powerful framework for collaborating centers committed to improving the understanding and treatment of these rare disorders.


  • Open Access

    Macrophage Lysosomal Alkalinization Drives Invasive Aspergillosis in a Mouse Cystic Fibrosis Model of Airway Transplantation

    by Efthymia Iliana Matthaiou, Wayland Chiu, Carol Conrad, Joe Hsu

    Cystic fibrosis (CF) lung transplant recipients (LTRs) exhibit a disproportionately high rate of life-threatening invasive aspergillosis (IA). Loss of the cystic fibrosis transmembrane conductance regulator (CFTR-/-) in macrophages (mφs) has been associated with lyosomal alkalinization. We hypothesize that this alkalinization would persist in the iron-laden post-transplant microenvironment increasing the risk of IA. To investigate our hypothesis, we developed a murine CF orthotopic tracheal transplant (OTT) model. Iron levels were detected by immunofluorescence staining and colorimetric assays. Aspergillus fumigatus (Af) invasion was evaluated by Grocott methenamine silver staining. Phagocytosis and killing of Af conidia were examined by flow cytometry and confocal microscopy. pH and lysosomal acidification were measured by LysoSensorTM and LysotrackerTM, respectively. Af was more invasive in the CF airway transplant recipient compared to the WT recipient (p < 0.05). CFTR-/- mφs were alkaline at baseline, a characteristic that was increased with iron-overload. These CFTR-/- mφs were unable to phagocytose and kill Af conidia (p < 0.001). Poly(lactic-co-glycolic acid) (PLGA) nanoparticles acidified lysosomes, restoring the CFTR-/- mφs’ ability to clear conidia. Our results suggest that CFTR-/- mφs’ alkalinization interacts with the iron-loaded transplant microenvironment, decreasing the CF-mφs’ ability to kill Af conidia, which may explain the increased risk of IA. Therapeutic pH modulation after transplantation could decrease the risk of IA.


  • Auto‐inflammation and auto‐immunity pathways are associated with emergence of BOS in pediatric lung transplantation

    by Carol K. Conrad, Haley Hedlin, Hyunsook Chin, Don Hayes, Peter S. Heeger, Albert Faro, Samuel Goldfarb, Ernestina Melicoff‐Portillo, Mohanakumar Thalachallour, Jonah Odim, et al.

    Background: Long‐term survival after lung transplantation (LTx) is limited by chronic lung allograft dysfunction (CLAD).Methods: We report an analysis of cytokine profiles in bronchoalveolar lavage samples collected during a prospective multicenter non‐interventional trial primarily designed to determine the impact of community‐acquired respiratory viral infections (CARV) in outcomes after pediatric LTx. In this analysis, we identify potential biomarkers of auto‐inflammation and auto‐immunity associated with survival and risk of bronchiolitis obliterans (BOS) after LTx with cytokine analysis of bronchoalveolar lavage fluid (BALF) from 61 pediatric recipients.Results: Higher IL‐23 (p = .048) and IL‐31 (p = .035) levels were associated with the risk of BOS, and lower levels of epithelial growth factor (EGF) (p = .041) and eotaxin (EOX) (p = .017) were associated with BOS. Analysis using conditional inference trees to evaluate cytokines at each visit associated with survival identified soluble CD30 (p < .001), pro‐inflammatory cytokine IL‐23 (p = .02), and sTNFRI (p = .01) below cutoff levels as associated with BOS‐free survival.Conclusions: Our results indicate that post‐LTx survival in children may be linked to activation of alternate pathways of the immune system that affect airway remodeling in addition to activation of “classical” pathways that have been described in adult LTx recipients. These may indicate pathways to target for intervention.


  • Open Access

    CTOTC-08: A multicenter randomized controlled trial of rituximab induction to reduce antibody development and improve outcomes in pediatric lung transplant recipients

    by Stuart C. Sweet, Brian Armstrong, Joshua Blatter, Hyunsook Chin, Carol Conrad, Samuel Goldfarb, Don Hayes, Peter S. Heeger, Victoria Lyou, Ernestina Melicoff-Portillo, et al.


  • Open Access

    Remote intervention engagement and outcomes in the Clinical Trials in Organ Transplantation in Children consortium multisite trial

    by Sarah Duncan-Park, Claire Dunphy, Jacqueline Becker, Christine D’uRso, Rachel Annunziato, Joshua Blatter, Carol Conrad, Samuel B. Goldfarb, Don Hayes Jr., Ernestina Melicoff, et al.


  • Epidemiology and persistence of rhinovirus in pediatric lung transplantation

    by Evan Ammerman, Stuart C. Sweet, Gregory A. Storch, Richard S. Buller, Sheila Mason, Carol Conrad, Don Hayes, Albert Faro, Samuel B. Goldfarb, Ernestina Melicoff, et al.

    Background: Infection with rhinovirus (HRV) occurs following pediatric lung transplantation. Prospective studies documenting frequencies, persistence, and progression of HRV in this at‐risk population are lacking.Methods: In the Clinical Trials in Organ Transplant in Children prospective observational study, we followed 61 lung transplant recipients for 2 years. We quantified molecular subtypes of HRV in serially collected nasopharyngeal (NP) and bronchoalveolar lavage (BAL) samples and correlated them with clinical characteristics.Results: We identified 135 community‐acquired respiratory infections (CARV) from 397 BAL and 480 NP samples. We detected 93 HRV events in 42 (68.8%) patients, 22 of which (23.4%) were symptomatic. HRV events were contiguous with different genotypes identified in 23 cases, but symptoms were not preferentially associated with any particular species. Nine (9.7%) HRV events persisted over multiple successive samples for a median of 36 days (range 18‐408 days). Three persistent HRV were symptomatic. When we serially measured forced expiratory volume in one second (FEV1) in 23 subjects with events, we did not observe significant decreases in lung function over 12 months post‐HRV.Conclusion: In conjunction with our previous reports, our prospectively collected data indicate that molecularly heterogeneous HRV infections occur commonly following pediatric lung transplantation, but these infections do not negatively impact clinical outcomes.


  • Update on pediatric lung transplantation: mir-ando into the mechanisms of chronic lung allograft dysfunction in children

    by Carol Conrad

    Purpose of review: Lung transplantation (LTx) is a worthwhile treatment for children with end-stage lung diseases who have no practicable medical or surgical solutions. But the long-term survival remains the lowest in all solid-organ transplant, with a median survival of 5.7 years, limited by the onset of chronic lung allograft dysfunction (CLAD). This reviews a recent publication in pediatric patients that focuses on translational regulation by microRNA. Recent findings: The mechanisms that cause transplanted lung allografts have been difficult to identify. This review discusses pertinent findings in the first and largest observational prospective study of pediatric lung transplant recipients. The review discusses the relevance of microRNA that distinguish stable patients from those who can be predicted to display graft dysfunction on a molecular panel. Summary: The article under review detected highly specific and sensitive markers of both acute rejection and CLAD in pediatric LTx recipients. With the use of next-generation sequencing techniques, biomarkers may soon provide the basis for earlier detection of graft function and stimulate development of therapeutic interventions to impact outcomes and survival. The review touches on the relevance of these findings and how future research can build on them.


  • Prior hepatectomy predicts local tumor progression and survival after percutaneous ablation of colorectal liver metastasis

    by B. Odisio, S. Yamashita, S. Huang, S. Kopetz, K. Ahrar, Y.S. Chun, C. Conrad, T. Aloia, M. Hicks, S. Gupta, et al.